Biomarkers in chronic graft-versus-host disease

References

• Gaziev J, Sodani P, Lucarelli G. Hematopoietic stem cell transplantation in thalassemia. Bone Marrow Transplant.42(Suppl. 1), S41 (2008).
   Google Scholar
• Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant.42(Suppl. 1), S49–S52 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta P, Locatelli F, Stary J, Smith FO. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr. Clin. North Am.57(1), 147–170 (2010).
   PubMed Web of Science ®Google Scholar
• Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br. J. Haematol.148(3), 356–372 (2010).
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol. Blood Marrow Transplant.16(Suppl. 1), S48–S56 (2010).
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic-graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transplant.11(12), 945–956 (2005).
   PubMed Web of Science ®Google Scholar
• Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood95(9), 2754–2759 (2000).
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med.363(22), 2091–2101 (2010).
   PubMed Web of Science ®Google Scholar
• Fraser C, Bhatia S, Ness K et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant. Survivor Study. Blood108(8), 2867–2873 (2006).
   PubMed Web of Science ®Google Scholar
• Lee SJ. Have me made progress in the management of chronic graft-vs-host disease?. Best Pract. Res. Clin. Haematol.23(4), 529–535 (2010).
   PubMed Web of Science ®Google Scholar
• Arora M, Burns LJ, Davies SM et al. Chronic graft-versus-host disease: a prospective cohort study. Biol. Blood Marrow Transplant.9(1), 38–45 (2003).
   PubMed Web of Science ®Google Scholar
• Bhatia S, Francisco L, Carter A et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood110(10), 3784–3792 (2007).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med.300(19), 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med.304(25), 1529–1533 (1981).
   PubMed Web of Science ®Google Scholar
• Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. Br. J. Haematol.147(5), 614–633 (2009).
   PubMed Web of Science ®Google Scholar
• Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood112(12), 4371–4383 (2008).
   PubMed Web of Science ®Google Scholar
• Olkinuora H, von Willebrand E, Kantele JM et al. The impact of early viral infections and graft-versus-host disease on immune reconstitution following pediatric stem cell transplantation. Scand. J. Immunol.14(2), 242–248 (2011).
   Google Scholar
• Cuthbert RJ, Iqbal A, Gates A, Toghill PJ, Russell NH. Functional hyposplenism following allogeneic bone marrow transplantation. J. Clin. Pathol.48(3), 257–259 (1995).
   PubMed Web of Science ®Google Scholar
• Roquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: a study of 53 long-term-surviving patients. Transplantation46(2), 238–240 (1988).
   PubMed Web of Science ®Google Scholar
• Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant.22(9), 873–881 (1998).
   PubMed Web of Science ®Google Scholar
• Ruoquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren’s syndrome and scleroderma. Br. J. Haematol.66(1), 45–47 (1987).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol. Blood Transplant.9(4), 215–233 (2003).
   PubMed Web of Science ®Google Scholar
• Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol. Blood Marrow Transplant.7(9), 495–502 (2001).
   PubMed Web of Science ®Google Scholar
• Arora M, Wagner JE, Davies SM et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol. Blood Marrow Transplant.7(5), 265–273 (2001).
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Reynolds C et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol. Blood Marrow Transplant.9(8), 505–511 (2003).
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood108(2), 756–762 (2006).
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant.40(3), 273–277 (2007).
   PubMed Web of Science ®Google Scholar
• Von Bonin M, Oelschlägel U, Radke J et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation86(6), 875–879 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston LJ, Brown J, Shizuru JA et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol. Blood Marrow Transplant.11(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Martin PJ, Storer BE, Rowley SD et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood113(21), 5074–5082 (2009).
   PubMed Web of Science ®Google Scholar
• Gilman AL, Chan KW, Mogul A et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol. Blood Marrow Transplant.6(3A), 327–334 (2000).
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Jacobsohn D, Anders V et al. Pentostatin in steroid-refractory chronic graft-versus-host disease. Blood106(11), 513A–514A (2005).
   Google Scholar
• Couriel DR, Hosing C, Saliba R et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood107(8), 3074–3080 (2006).
   PubMed Web of Science ®Google Scholar
• Soiffer RJ. Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant.42(Suppl. 1), S66–S69 (2008).
   Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.69(3), 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Schultz KR, Miklos DB, Fowler D et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol. Blood Marrow Transplant.12(2), 126–137 (2006).
   PubMed Web of Science ®Google Scholar
• Greinix HT, Fae I, Schneider B et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant.35(1), 57–62 (2005).
   PubMed Web of Science ®Google Scholar
• Morishima Y, Sasazuki T, Inoko H et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood99(11), 4200–4206 (2002).
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Baxter-Lowe LA, Confer D et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood104(7), 1923–1930 (2004).
   PubMed Web of Science ®Google Scholar
• Teshima T, Matsuo K, Matsue K et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br. J. Haematol.130(4), 575–587 (2005).
   PubMed Web of Science ®Google Scholar
• Woolfrey A, Klein JP, Haagenson M et al. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant.17(6), 885–892 (2010).
   PubMed Web of Science ®Google Scholar
• Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N. Engl. J. Med.339(22), 1565–1577 (1998).
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rocha V, Arcese W et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp. Hematol.32(4), 397–407 (2004).
   PubMed Web of Science ®Google Scholar
• Alsultan A, Giller RH, Gao D et al. GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplant.46(5), 668–675 (2011).
   PubMed Web of Science ®Google Scholar
• Herr AL, Kabbara N, Bonfim CM et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood116(11), 1849–1856 (2010).
   PubMed Web of Science ®Google Scholar
• Arora M, Nagaraj S, Wagner JE et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol. Blood Marrow Transplant.13(10), 1145–1152 (2007).
   PubMed Web of Science ®Google Scholar
• Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med.5(7), 839–842 (1999).
   PubMed Web of Science ®Google Scholar
• Loren AW, Bunin GR, Boudreau C et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. 12(7), 758–769 (2006).
   Google Scholar
• Gahrton G. Risk assessment in haematopoietic stem cell transplantation: impact of donor–recipient sex combination in allogeneic transplantation. Best Pract. Res. Clin. Haematol.20(2), 219–229 (2007).
   PubMed Web of Science ®Google Scholar
• Spellman S, Warden MB, Haagenson M et al. Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. Biol. Blood Marrow Transplant.15(7), 856–863 (2009).
   PubMed Web of Science ®Google Scholar
• Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood115(11), 2319–2328 (2010).
   PubMed Web of Science ®Google Scholar
• Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod. Pathol.20(1), 8–14 (2007).
   PubMed Web of Science ®Google Scholar
• Li RW, Freeman C, Yu D et al. Dramatic regulation of heparanase expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum.58(6), 1590–1600 (2008).
   PubMedGoogle Scholar
• Arora M, Lindgren B, Basu S et al. Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia24(8), 1470–1475 (2010).
   PubMed Web of Science ®Google Scholar
• Ambruzova Z, Mrazek F, Raida L et al. Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation. Hum. Immunol.70(6), 457–460 (2009).
   PubMed Web of Science ®Google Scholar
• McGuirk J, Hao G, Hou W et al. Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation. J. Hematol. Oncol.2, 17 (2009).
   PubMedGoogle Scholar
• Arredouani M, Matthijs P, Van Hoeyveld E et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology108(2), 144–151 (2003).
   PubMed Web of Science ®Google Scholar
• Pagano M, Nicola MA, Engler R. Inhibition of cathepsin L and B by haptoglobin, the haptoglobin-hemoglobin complex, and asialohaptoglobin. ‘In vitro’ studies in the rat. Can. J. Biochem.60(6), 631–637 (1982).
   PubMedGoogle Scholar
• Sadrzadeh SM, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am. J. Clin. Pathol.121(Suppl.), S97–S104 (2004).
   PubMedGoogle Scholar
• Shimada M, Onizuka M, Machida S et al. Association of autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. Br. J. Haematol.139(3), 458–463 (2007).
   PubMed Web of Science ®Google Scholar
• Kochi Y, Yamada R, Suzuki A et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat. Genet.37(5), 478–485 (2005).
   PubMed Web of Science ®Google Scholar
• Kornblit B, Masmas T, Petersen SL et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant.16(2), 239–252 (2010).
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells trigger inflammation. Nature418(6894), 191–195 (2002).
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Baruah P, Valentinis B et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol.174(12), 7506–7515 (2005).
   PubMed Web of Science ®Google Scholar
• Ek M, Popovic K, Harris HE, Nauclér CS, Wahren-Herlenius M. Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum.54(7), 2289–2294 (2006).
   PubMed Web of Science ®Google Scholar
• Popovic K, Ek M, Espinosa A et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum.52(11), 3639–3645 (2005).
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Murata M, Katsumi A et al. Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone Marrow Transplant.45(2), 363–369 (2010).
   PubMed Web of Science ®Google Scholar
• Sivula J, Turpeinen H, Volin L, Partanen J. Association of IL-10 and IL-10Rβ gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunol.10, 24 (2009).
   PubMed Web of Science ®Google Scholar
• Kim DH, Lee NY, Sohn SK et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation79(11), 1615–1622 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Furukawa T, Hashimoto S et al. Contribution of TNF-α and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant.26(12), 1317–1323 (2000).
   PubMed Web of Science ®Google Scholar
• Bertinetto FE, Dall’Omo AM, Mazzola GA et al. Role of non-HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell transplantation. Int. J. Immunogenet.33(5), 375–384 (2006).
   PubMed Web of Science ®Google Scholar
• Viel DO, Tsuneto LT, Sossai CR et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand. J. Immunol.66(6), 703–710 (2007).
   PubMed Web of Science ®Google Scholar
• Laguila Visentainer JE, Lieber SR, Lopes Persoli LB et al. Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine32(3–4), 171–177 (2005).
   PubMed Web of Science ®Google Scholar
• Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of interleukin-1α constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br. J. Haematol.122(5), 778–787 (2003).
   PubMed Web of Science ®Google Scholar
• Rocha V, Franco RF, Porcher R et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood100(12), 3908–3918 (2002).
   PubMed Web of Science ®Google Scholar
• Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipient interferon-γ 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica90(3), 425–426 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka J, Imamura M, Kasai M et al. Th2 cytokines (IL-4, IL-10 and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood mononuclear cells during chronic graft-versus-host disease. Eur. J. Haematol.57(1), 111–113 (1996).
   PubMed Web of Science ®Google Scholar
• Skert C, Damiani D, Michelutti A et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant.44(11), 729–737 (2009).
   PubMed Web of Science ®Google Scholar
• Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk. Lymphoma17(1–2), 169–173 (1995).
   PubMed Web of Science ®Google Scholar
• Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis factor α and interferon γ to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant.11(9), 706–712 (2005).
   PubMed Web of Science ®Google Scholar
• Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology8(1), 19–26 (2003).
   PubMedGoogle Scholar
• Fimiani M, De Aloe G, Cuccia A. Chronic graft versus host disease and skin. J. Eur. Acad. Dermatol. Venerol.17(5), 512–517 (2003).
   PubMed Web of Science ®Google Scholar
• Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis α and interferon γ to predict the onset of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant.11(9), 706–712 (2005).
   PubMed Web of Science ®Google Scholar
• Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant.17(6), 1085–1092 (1996).
   PubMed Web of Science ®Google Scholar
• Rozmus J, Schultz KR, Wynne K et al. Early and late extensive chronic graft-versus-host disease (cGVHD) in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children’s Oncology Group Study (COG), ASCT0031. Biol. Blood Marrow Transplant. (2011) (In Press).
   PubMedGoogle Scholar
• Meignin V, Peffault de Latour R, Zuber J et al. Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. Exp. Hematol.33(8), 894–900 (2005).
   PubMed Web of Science ®Google Scholar
• Clark FJ, Gregg R, Piper K et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood103(6), 2410–2416 (2004).
   PubMed Web of Science ®Google Scholar
• Miura Y, Thoburn CJ, Bright EC. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood104(7), 2187–2193 (2004).
   PubMed Web of Science ®Google Scholar
• Li Q, Zhai Z, Xu X et al. Decrease of CD4+CD25+ regulatory T cells and TGF-β at early immune reconstitution is associated to the onset and severity of graft-versus-host disease following allogeneic haematogenesis stem cell transplantation. Leuk. Res.34(9), 1158–1168 (2010).
   PubMed Web of Science ®Google Scholar
• Zorn E, Kim HT, Lee SJ et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood106(8), 2903–2911 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kim HT, McDonough S et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest.120(5), 1479–1493 (2010).
   PubMed Web of Science ®Google Scholar
• Giorgini A, Noble A. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts. J. Leuk. Biol.82(5), 1053–1061 (2007).
   PubMed Web of Science ®Google Scholar
• Allan SE, Crome SQ, Crellin NK et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol.19(4), 345–354 (2007).
   PubMed Web of Science ®Google Scholar
• Popmihajlov Z, Smith KA. Negative feedback regulation of T cells via interleukin-2 and FOXP3 reciprocity. PLoS One3(2), e1581 (2008).
   Google Scholar
• Yamashita K, Choi U, Woltz PC et al. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4+ effector memory cells relative to central memory cells. Blood103(10), 3986–3988 (2004).
   PubMed Web of Science ®Google Scholar
• D’Asaro M, Salerno A, Dieli F, Caccamo N. Analysis of memory and effector CD8+ T cell subsets in chronic graft-versus-host disease. Int. J. Immunopathol. Pharmacol.22(1), 195–205 (2009).
   PubMed Web of Science ®Google Scholar
• Sato M, Tokuda N, Fukumoto T, Mano T, Sato T, Ueyama Y. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol. Med.35(1), 33–36 (2006).
   PubMed Web of Science ®Google Scholar
• Dander E, Balduzzi A, Zappa G et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation88(11), 1261–1272 (2009).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Inaba K. Myeloid dendritic cells. J. Leuk. Biol.66(2), 205–208 (1999).
   PubMed Web of Science ®Google Scholar
• Waller EK, Rosenthal H, Jones TW et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood97(10), 2948–2956 (2001).
   PubMed Web of Science ®Google Scholar
• Rajasekar R, Mathews V, Lakshmi KM et al. Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood stem cell transplant predicts the incidence of acute and chronic GVHD. Biol. Blood Marrow Transplant.14(3), 344–350 (2008).
   PubMed Web of Science ®Google Scholar
• Arpinati M, Chirumbolo G, Bandini G et al. GVHD affects DC-2 recovery after allogeneic PBSC transplantation. Bone Marrow Transplant.29(Suppl. 2), 661 (2002).
   Google Scholar
• Arpinati M, Chirumbolo G, Marzocchi G, Baccarani M, Rondelli D. Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. Transplantation85(12), 1826–1832 (2008).
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood98(6), 1695–1700 (2001).
   PubMed Web of Science ®Google Scholar
• Kalaycioglu ME, Bolwell BJ. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. Bone Marrow Transplant.14(1), 113–115 (1994).
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am. J. Med.69(2), 204–217 (1980).
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation77(7), 1096–1100 (2004).
   PubMed Web of Science ®Google Scholar
• Lan F, Zeng D, Higuchi M, Hule P, Higgins JP, Strober S. Predominance of NK1.1+TC αβ+ or DX5+TCRαβ+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: ‘natural suppressor’ cells. J. Immunol.167(4), 2087–2096 (2001).
   PubMed Web of Science ®Google Scholar
• Lan F, Zeng D, Higuchi M, Higgins JP, Strober S. Host conditioning with total lymphoid irradiation and anti-thymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol. Blood Marrow Transplant.9(6), 355–363 (2003).
   PubMed Web of Science ®Google Scholar
• Pillai AB, George TI, Dutt S, Strober S. Host natural killer T cells induce an IL-4 dependent expansion of donor CD4+CD25+Foxp3+ Tregs that protects against graft-versus-host disease. Blood113(18), 4458–4467 (2009).
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Turnbull BB, Heydari K et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood114(5), 1099–1109 (2009).
   PubMed Web of Science ®Google Scholar
• Larghero J, Rocha V, Porcher R et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br. J. Haematol.138(1), 101–109 (2007).
   PubMed Web of Science ®Google Scholar
• Skert C, Damiani D, Michelutti A et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant.44(11), 729–737 (2009).
   PubMed Web of Science ®Google Scholar
• Imamura M, Tsutsumi Y, Miura Y, Toubai T, Tanaka J. Immune reconstitution and tolerance after allogeneic hematopoietic stem cell transplantation. Hematology8(1), 19–26 (2003).
   PubMedGoogle Scholar
• Ruggeri L, Mancusi A, Burchielli E et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol. Dis.40(1), 84–90 (2008).
   PubMed Web of Science ®Google Scholar
• Schultz KR, Paquet J, Bader S, Hayglass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant.16(2), 289–295 (1995).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee JW, Jung CW et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective multicenter Phase II study. Haematologica95(11), 1935–1942 (2010).
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Zorn E et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood103(1), 353–359 (2004).
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood105(7), 2973–2978 (2005).
   PubMed Web of Science ®Google Scholar
• Patriarca F, Skert C, Sperotto A et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp. Hematol.34(3), 389–396 (2006).
   PubMed Web of Science ®Google Scholar
• Kier P, Penner E, Bakos S et al. Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant.6(2), 93–96 (1990).
   PubMed Web of Science ®Google Scholar
• Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin. Lab. Haematol.27(4), 247–249 (2005).
   PubMedGoogle Scholar
• Quaranta S, Shulman H, Ahmed A et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin. Immunol.91(1), 106–116 (1999).
   PubMed Web of Science ®Google Scholar
• Moon JH, Lee SJ, Kim JG et al. Clinical significance of autoantibody expression in allogeneic stem-cell recipients. Transplantation88(2), 242–250 (2009).
   PubMed Web of Science ®Google Scholar
• Fujii H, Cuvelier G, She K et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood111(6), 3276–3285 (2008).
   PubMed Web of Science ®Google Scholar
• Svegliati S, Olivieri A, Campelli N et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood110(1), 237–241 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol.166(1), 6–10 (2001).
   PubMed Web of Science ®Google Scholar
• Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum.44(6), 1313–1319 (2001).
   PubMed Web of Science ®Google Scholar
• Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J. Clin. Invest.109(1), 59–68 (2002).
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity20(6), 785–798 (2004).
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin. Cancer Res.13(20), 6107–6014 (2007).
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood117(7), 2275–2283 (2011).
   PubMed Web of Science ®Google Scholar
• Daridon C, Devauchelle V, Hutin P et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum.56(4), 1134–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Morimoto S, Nakano S, Watanabe T et al. Expression of BAFF in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford)46(7), 1083–1086 (2007).
   PubMed Web of Science ®Google Scholar
• Thanou-Stavraki A, Sawalha AH. An update on belimumab for the treatment of lupus. Biologics5, 33–43 (2011).
   PubMedGoogle Scholar
• She K, Gilman AL, Asianian S et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol. Blood Marrow Transplant.13(4), 386–397 (2007).
   PubMed Web of Science ®Google Scholar
• D’Orsogna LJ, Wright MP, Krueger RG et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol. Blood Marrow Transplant.15(7), 795–803 (2009).
   PubMed Web of Science ®Google Scholar
• Greinix HT, Pohlreich D, Kouba M et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol. Blood Marrow Transplant.14(2), 208–219 (2008).
   PubMed Web of Science ®Google Scholar
• Isnardi I, Ng YS, Menard L et al. Complement receptor 2/CD21-negative human naive B cells mostly contain autoreactive unresponsive clones. Blood115(24), 5026–5036 (2010).
   PubMed Web of Science ®Google Scholar
• Kuzmina Z, Greinix HT, Weigl R et al. Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease associated dysgammaglobulinemia. Blood117(7), 2265–2274 (2011).
   PubMed Web of Science ®Google Scholar
• Perruche S, Marandin A, Kleinclauss F et al. Association of mixed hematopoietic chimerism with elevated circulating autoantibodies and chronic graft-versus-host disease occurrence. Transplantation81(4), 573–582 (2006).
   PubMed Web of Science ®Google Scholar
• Cuvelier GD, Kariminia A, Fujii H et al. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children’s Oncology Groups Study, ASCT0031. Bone Marrow Transplant.45(11), 1653–1670 (2010).
   PubMed Web of Science ®Google Scholar
• Larsen SL, Pedersen LO, Buus S, Stryhn A. T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J. Exp. Med.184(1), 183–189 (1996).
   PubMed Web of Science ®Google Scholar
• Tani K, Ogushi F, Huang L et al. CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med.161(5), 1636–1642 (2000).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tani K, Hase K et al. CD13/aminopeptidase N-induced lymphocyte involvement in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum.46(9), 2330–2338 (2002).
   PubMedGoogle Scholar
• Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk. Lymphoma28(1–2), 159–169 (1997).
   PubMed Web of Science ®Google Scholar
• Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation66(7), 863–871 (1998).
   PubMed Web of Science ®Google Scholar
• Balon J, Halaburda K, Bieniaszewska M et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. Bone Marrow Transplant.35(11), 1083–1088 (2005).
   PubMed Web of Science ®Google Scholar
• Pavletic SZ, Smith LM, Bishop MR et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am. J. Hematol.78(4), 265–274 (2005).
   PubMed Web of Science ®Google Scholar
• Sohn SK, Kim DH, Baek JH et al. Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant.37(7), 699–708 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Choi SJ et al. Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. Br. J. Haematol.122(4), 673–644 (2003).
   Google Scholar
• Izutsu KT, Schubert MM, Truelove EL et al. The predictive value of elevated labial saliva sodium concentration: its relation to labial gland pathology in bone marrow transplant recipients. Hum. Pathol.14(1), 29–35 (1983).
   PubMed Web of Science ®Google Scholar
• Izutsu KT, Menard TW, Schubert MM et al. Graft versus host disease-related secretory immunoglobulin A deficiency in bone marrow transplant recipients. Findings in labial saliva. Lab. Invest.52(3), 292–297 (1985).
   PubMed Web of Science ®Google Scholar
• Izutsu KT, Sullivan KM, Schubert MM et al. Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplantation35(5), 441–446 (1983).
   PubMed Web of Science ®Google Scholar
• Boutin M, Ahmad I, Jauhiainen M et al. NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. Anal. Chem.81(22), 9454–9461 (2009).
   PubMed Web of Science ®Google Scholar